🇺🇸 FDA
Pipeline program

ETC-1002

ETC-1002-004

Phase 1 small_molecule completed

Quick answer

ETC-1002 for Safety Evaluation of Escalating Doses is a Phase 1 program (small_molecule) at Esperion Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Esperion Therapeutics
Indication
Safety Evaluation of Escalating Doses
Phase
Phase 1
Modality
small_molecule
Status
completed

Clinical trials